Recombinant Cynomolgus Monkey LAIR2 Fc Chimera Protein, CF

When Bovine Collagen I is coated at 10 μg/mL (100 μL/well), Recombinant Cynomolgus Monkey LAIR2 Fc Chimera (Catalog # 10340-LR) binds with an ED50 of 0.04-0.32 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey LAIR2 Fc Chimera (Catalog # 10340-LR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 53-60 kDa and 100-120 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey LAIR2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  When Bovine Collagen I is coated at 10 µg/mL (100 μL/well), Recombinant Cynomolgus Monkey LAIR2 Fc Chimera (Catalog # 10340-LR) binds with an ED50 of 0.04-0.32 ng/mL.

• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey LAIR2 protein
  

  Cynomolgus Monkey LAIR2 (Gln22-Ser152) Accession # XP_005590391.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005590391.1
• N-terminal Sequence: Gln22 deduced from Glu23 after deblocking.
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 41 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 53-60 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey LAIR2 Fc Chimera Protein, CF

• CD306 antigen
• CD306
• CD306leukocyte-associated Ig-like receptor-2
• LAIR2
• LAIR-2
• leukocyte-associated Ig-like receptor 2
• leukocyte-associated immunoglobulin-like receptor 2
• MGC71634

Background

LAIR2 (leukocyte-associated Ig-like receptor-2; CD306) is a secreted protein that contains one Ig-like C2 type domain, making it a member of the Ig superfamily. Cynomolgus LAIR-2 cDNA encodes a 152 amino acid (aa) polypeptide precursor. Based on the similarity with human LAIR2, it likely includes a 21 aa signal peptide and a 131 aa mature chain. Cynomolgus LAIR2 shares 78% aa identity with human LAIR2. When compared to LAIR1, its transmembrane counterpart, LAIR2 shares 83% aa identity across the signal sequence and extracellular domains (1-3). Although one is secreted and the other is membrane-bound, the two LAIR proteins are thought to have arisen from a common gene ancestor and appear to share similar adhesion profiles. This suggests that LAIR2 may compete with LAIR1 for ligand binding (3, 4). The expression profile of these splice forms, and the presence of orthologs in other species, have not been reported. LAIR2 is a soluble collagen-receptor, and it can be detected in the synovial fluid of rheumatoid arthritis patients, urine of pregnant women, and as well as primary cells (5, 6). In vitro studies have demonstrated LAIR2 can compete with LAIR1 for the same collagen binding site and suggesting LAIR2 may play an important role in immune cell activation (5, 6). LAIR2 can interact with complement component 1q (C1q) and mannose-binding lectin (MBL) and act as a complement inhibitor for the treatment and prevention of antibody-mediated allograft rejection and antibody-mediated clinical conditions (7).

1. Meyaard, L. (2003) J. Biol. Regul. Homeost. Agents 17:330.
2. Meyaard, L. et al. (1999) J. Immunol. 162:5800.
3. Meyaard, L. et al. (1997) Immunity 7:283.
4. Xu, X.G. et al. (2005) Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 21:553.
5. Lebbink, R.J. et al. (2008) J. Immunol. 180:1662.
6. Olde Nordkamp, M.J. et al. (2011) Arthritis Rheum. 63:3749.
7. Olde Nordkamp, M.J. et al. (2014) J. Innate Immun. 6:284.

Bioinformatics

• Uniprot:
  • XP_005590391.1()